Paraoxonase activity in healthy, diabetic, and hemodialysis patients

Clinical Biochemistry

Volumn 45, Issue 6, 2012, Pages 470-474

  Gbandjaba, Nagba Yendoubé ^a,b,d   Ghalim, Noreddine ^b   Hassar, Mohamed ^b   Berrougui, Hicham ^c,d   Labrazi, Halima ^a   Taki, Hassan ^a   Saile, Rachid ^a   Khalil, Abdelouahed ^d  

^a FACULTÉ DES SCIENCES BEN M SIK   (Morocco)

^b Institut Pasteur du Maroc   (Morocco)

^c SULTAN MOULAY SLIMANE UNIVERSITY   (Morocco)

^d UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

Hemodialysis; MDA; Oxidative stress; PON1; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; CHOLESTEROL; MALONALDEHYDE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; HEALTH STATUS; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; ARYLDIALKYLPHOSPHATASE; CARBOXYLIC ESTER HYDROLASES; DIABETES MELLITUS, TYPE 2; FEMALE; GENE FREQUENCY; HEALTH; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; PHENOTYPE; RENAL DIALYSIS; THIOBARBITURIC ACID REACTIVE SUBSTANCES; VITAMIN E;

EID: 84858444492     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.01.005     Document Type: Article

References (36)

1. Durrington P.N., Mackness B., Mackness M.I. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001, 21:473-480.
2. Jaouad L., de Guise C., Berrougui H., Cloutier M., Isabelle M., Fulop T., et al. Age-related decrease in high-density lipoproteins antioxidant activity is due to an alteration in the PON1's free sulfhydyl groups. Atherosclerosis 2006, 185:191-200.
3. Jarvik G.P., Rozek L.S., Brophy V.H., Hatsukami T.S., Richter R.J., Schellenberg G.D., et al. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler Thromb Vasc Biol 2000, 20:2441-2447.
4. Ikeda Y., Suehiro T., Inoue M., Nakauchi Y., Morita T., Arii K., et al. Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus. Metabolism 1998, 47:598-602.
5. Abbott C.A., Mackness M.I., Kumar S., Boulton A.J., Durrington P.N. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 1995, 15:1812-1818.
6. Tomas M., Senti M., Garcia-Faria F., Vila J., Torrents A., Covas M., et al. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2000, 20:2113-2119.
7. Sies H. Oxidative stress: oxidants and antioxidants. Exp Physiol 1997, 82:291-295.
8. Beyer R.E. The role of ascorbate in antioxidant protection of biomembranes: interaction with vitamin E and coenzyme Q. J Bioenerg Biomembr 1994, 26:349-358.
9. Gerber M., Saintot M. Re: Prospective study of serum micronutrients and ovarian cancer. J Natl Cancer Inst 1997, 89:581-582.
10. Ford L., Farr J., Morris P., Berg J. The value of measuring serum cholesterol-adjusted vitamin E in routine practice. Ann Clin Biochem 2006, 43:130-134.
11. Gan K.N., Smolen A., Eckerson H.W., La Du B.N. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 1991, 19:100-106.
12. Paragh G., Asztalos L., Seres I., Balogh Z., Locsey L., Karpati I., et al. Serum paraoxonase activity changes in uremic and kidney-transplanted patients. Nephron 1999, 83:126-131.
13. Miller N.E., La Ville A., Crook D. Direct evidence that reverse cholesterol transport is mediated by high-density lipoprotein in rabbit. Nature 1985, 314:109-111.
14. Seres I., Paragh G., Deschene E., Fulop T., Khalil A. Study of factors influencing the decreased HDL associated PON1 activity with aging. Exp Gerontol 2004, 39:59-66.
15. Milochevitch C., Khalil A. Study of the paraoxonase and platelet-activating factor acetylhydrolase activities with aging. Prostaglandins Leukot Essent Fatty Acids 2001, 65:241-246.
16. Berrougui H., Cloutier M., Isabelle M., Khalil A. Phenolic-extract from argan oil (Argania spinosa L.) inhibits human low-density lipoprotein (LDL) oxidation and enhances cholesterol efflux from human THP-1 macrophages. Atherosclerosis 2006, 184:389-396.
17. Agarwal R., Chase S.D. Rapid, fluorimetric-liquid chromatographic determination of malondialdehyde in biological samples. J Chromatogr B Analyt Technol Biomed Life Sci 2002, 775:121-126.
18. Anavekar N.S., McMurray J.J., Velazquez E.J., Solomon S.D., Kober L., Rouleau J.L., et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004, 351:1285-1295.
19. Sela S., Shurtz-Swirski R., Shapiro G., Nasser L., Hamzi M., Shasha S.M., et al. Oxidative stress during hemodialysis: effect of heparin. Kidney Int Suppl 2001, 78:S159-S163.
20. Lehmann R., Spinas G.A. Diabetic nephropathy: significance of microalbuminuria and proteinuria in Type I and Type II diabetes mellitus. Praxis 1995, 84:1265-1271.
21. Chiarelli F., Verrotti A., Mohn A., Morgese G. The importance of microalbuminuria as an indicator of incipient diabetic nephropathy: therapeutic implications. Ann Med 1997, 29:439-445.
22. Tabak O., Gelisgen R., Erman H., Erdenen F., Muderrisoglu C., Aral H., et al. Oxidative lipid, protein, and DNA damage as oxidative stress markers in vascular complications of diabetes mellitus. Clin Invest Med 2011, 34:E163-E171.
23. Montazerifar F., Hashemi M., Karajibani M., Dikshit M. Hemodialysis alters lipid profiles, total antioxidant capacity, and vitamins A, E, and C concentrations in humans. J Med Food 2010, 13:1490-1493.
24. Kontush A., Chapman M.J. Why is HDL functionally deficient in type 2 diabetes?. Curr Diab Rep 2008, 8:51-59.
25. Vaziri N.D., Navab M., Fogelman A.M. HDL metabolism and activity in chronic kidney disease. Nat Rev Nephrol 2010, 6:287-296.
26. Sampson M.J., Braschi S., Willis G., Astley S.B. Paraoxonase-1 (PON-1) genotype and activity and in vivo oxidized plasma low-density lipoprotein in Type II diabetes. Clin Sci (Lond) 2005, 109:189-197.
27. Deakin S., Leviev I., Brulhart-Meynet M.C., James R.W. Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant role for polymorphic position -107, implicating the Sp1 transcription factor. Biochem J 2003, 372:643-649.
28. Kumon Y., Nakauchi Y., Kidawara K., Fukushima M., Kobayashi S., Ikeda Y., et al. A longitudinal analysis of alteration in lecithin-cholesterol acyltransferase and paraoxonase activities following laparoscopic cholecystectomy relative to other parameters of HDL function and the acute phase response. Scand J Immunol 1998, 48:419-424.
29. Inoue M., Suehiro T., Nakamura T., Ikeda Y., Kumon Y., Hashimoto K. Serum arylesterase/diazoxonase activity and genetic polymorphisms in patients with type 2 diabetes. Metabolism 2000, 49:1400-1405.
30. Ginsberg G., Neafsey P., Hattis D., Guyton K.Z., Johns D.O., Sonawane B. Genetic polymorphism in paraoxonase 1 (PON1): population distribution of PON1 activity. J Toxicol Environ Health B Crit Rev 2009, 12:473-507.
31. Imai Y., Morita H., Kurihara H., Sugiyama T., Kato N., Ebihara A., et al. Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Atherosclerosis 2000, 149:435-442.
32. Vaisi-Raygani A., Ghaneialvar H., Rahimi Z., Tavilani H., Pourmotabbed T., Shakiba E., et al. Paraoxonase Arg 192 allele is an independent risk factor for three-vessel stenosis of coronary artery disease. Molecular biology reports 2011.
33. Ruiz J., Blanche H., James R.W., Garin M.C., Vaisse C., Charpentier G., et al. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 1995, 346:869-872.
34. Sutherland W.H., Manning P.J., de Jong S.A., Allum A.R., Jones S.D., Williams S.M. Hormone-replacement therapy increases serum paraoxonase arylesterase activity in diabetic postmenopausal women. Metabolism 2001, 50:319-324.
35. Valabhji J., McColl A.J., Schachter M., Dhanjil S., Richmond W., Elkeles R.S. High-density lipoprotein composition and paraoxonase activity in Type I diabetes. Clin Sci 2001, 101:659-670.
36. Hedrick C.C., Thorpe S.R., Fu M.X., Harper C.M., Yoo J., Kim S.M., et al. Glycation impairs high-density lipoprotein function. Diabetologia 2000, 43:312-320.